Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 653 trials

Nephrotic Syndrome: Rituximab Treatment Comparison

We are comparing two Rituximab treatment plans for adults with relapsing nephrotic syndrome. The goal is to find out which regimen better prevents relapses and improves quality of life.

Nephrotic Syndrome1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyNephrology

Early Alzheimer's Disease: Sabirnetug Infusions

We are studying whether intravenous sabirnetug can slow cognitive decline in people with early Alzheimer's disease compared to a placebo. This trial aims to find new ways to help manage symptoms and improve quality of life.

Early Alzheimer's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Liver Cirrhosis: Stopping Proton-Pump Inhibitors

We are studying whether stopping proton-pump inhibitors helps or harms patients with liver cirrhosis compared to those who continue the medication. This trial looks at hospitalizations, infections, and overall health outcomes.

Liver Cirrhosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesGastroenterologyInternal Medicine

DOK7 Congenital Myasthenic Syndrome: ARGX-119 Study

We are investigating the safety and tolerability of a new treatment, ARGX-119, for adults with DOK7 Congenital Myasthenic Syndrome. This study aims to understand how well the treatment is tolerated in this specific group.

Congenital Myasthenic Syndrome1-2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineNeurology

Severe von Willebrand Disease: Vonicog Alfa Prophylaxis

We are studying whether vonicog alfa can help prevent bleeding episodes in children with severe von Willebrand disease. The trial will also look at the safety of this treatment over time.

Von Willebrand Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

ZP9830: New Medication Study

We are testing different doses of ZP9830 in healthy volunteers to see how it affects the body. This research helps us find safe dosage levels for future treatments.

Autoimmune Diseases1-2 yearsSafety phase (I)Internal Medicine

Kidney Transplant: BIVV020 for Rejection Prevention and Treatment

We are studying BIVV020 to see if it can help prevent or treat antibody-mediated rejection in adults who have received a kidney transplant. This trial will assess its safety and how well it works compared to current treatments.

Transplant Rejection1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyInfectious DiseasesInternal MedicineOncology

Tranexamic Acid for Reducing Blood Transfusions in Abdominal Surgery

We are studying whether Tranexamic Acid can lower blood loss and the need for blood transfusions during major abdominal surgeries. This trial also examines safety and recovery outcomes for patients.

Intraoperative Bleeding1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesHematologyOrthopedics and Traumatology

Inebilizumab for Children with Neuromyelitis Optica Spectrum Disorder

We are studying how the medication inebilizumab affects children and adolescents with NMOSD. The trial will help us learn about its safety and how it impacts their health and daily life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Safety Study of AIC263029 Medication

We are investigating whether AIC263029 is safe when given once or multiple times. This study will also look at how the medication moves through the body.

BK Virus Nephropathy1-2 yearsSafety phase (I)Infectious DiseasesNephrology

Cerebral Amyloid Angiopathy: ALN-APP Treatment Study

We are studying a new treatment called ALN-APP for patients with Cerebral Amyloid Angiopathy. The goal is to see if it helps reduce new brain bleeding and improve overall brain health.

Cerebral Amyloid Angiopathy1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Systemic Lupus Erythematosus: Rapcabtagene Autoleucel Study

We are studying a new treatment for people with difficult-to-treat kidney disease caused by systemic lupus erythematosus. The goal is to see if it works better than standard care in improving kidney health.

Systemic Lupus Erythematosus with Lupus Nephritis1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrologyRheumatology

Rheumatoid Arthritis: Proactive Drug Monitoring Study

We are investigating whether proactive monitoring of a TNF inhibitor helps adults with rheumatoid arthritis maintain better disease control without flare-ups compared to standard care.

Rheumatoid Arthritis1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesRheumatology

Takotsubo Syndrome: Beta-Blockers Study

We are investigating whether beta-blockers can help improve heart function in patients with Takotsubo Syndrome. This study will also look at various heart health measures and quality of life.

Takotsubo Syndrome1-2 yearsMonitoring phase (IV)6-10 visitsPartially RemoteCardiologyInternal Medicine

Recurrent Glioblastoma: Personalized Drug Strategy

We are testing a personalized treatment approach for patients with recurrent glioblastoma to see if tailored drug combinations improve tumor response and overall survival. The study also looks at any side effects from the treatments.

Recurrent Glioblastoma1-2 yearsSafety phase (I)No PlaceboStandard MedicinesNeurologyOncology

Bronchiectasis: Inhaled Antibiotics Study

We are studying whether inhaled antibiotics can help reduce bacterial infections in patients with bronchiectasis after initial treatment. This trial compares the effects of inhaled antibiotics to a placebo.

Adult Bronchiectasis1-2 yearsStandard MedicinesInternal MedicinePulmonology

Pamidronate for Pain in Sternocostoclavicular Hyperostosis

We are studying whether pamidronate can help reduce pain in patients with sternocostoclavicular hyperostosis. This trial will also look at improvements in daily activities and overall health.

Inflammation of the Sternal RegionSternocostoclavicular Hyperostosis1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesOrthopedics and TraumatologyRheumatology

Hypereosinophilic Syndrome: Depemokimab Study

We are investigating whether Depemokimab can help adults with Hypereosinophilic Syndrome manage their symptoms better than a placebo. This study aims to provide insights into its effectiveness and safety.

Hypereosinophilic Syndrome1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Severe Diffuse Cutaneous Systemic Sclerosis: Rapcabtagene Autoleucel vs. Rituximab

We are studying a new treatment to see if it works better than rituximab for people with severe diffuse cutaneous systemic sclerosis. The trial will also evaluate the safety of this new therapy.

Systemic Scleroderma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Postoperative Sleep Quality: DEXSLEEP Study

We are testing whether dexmedetomidine can improve sleep and reduce fatigue in elderly patients after major surgery. This may help enhance recovery and overall well-being following surgery.

Healthy Participants Aged 60 and Older1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPsychiatry